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Shiga-like toxin (SLT)-producing Escherichia coli has been associated with a spectrum of human illnesses,
including hemorrhagic colitis and hemolytic uremic syndrome. It produces at least two antigenically distinct
toxins designated SLT-I and SLT-II, which have been implicated in disease. Currently available toxin assays,
however, are not suitable for most clinical or public health laboratories. In this study, we have developed two
sandwich enzyme-linked immunosorbent assays (ELISAs) based on toxin-specific murine monoclonal capture
antibodies and rabbit polyclonal second antibodies which are specific for SLT-I and SLT-II. The SLT-I ELISA
detected 200 pg of purified SLT-I, and the SLT-II ELISA detected 75 pg of purified SLT-II. The types of SLT
produced by 166 human and 54 animal isolates of E. coli that produced moderate to high levels of toxin were
determined by the ELISA, and results were confirmed by cytotoxin neutralization assays. With the exception
of results from three strains, the tests agreed on the types of toxin present. DNA probe assays of 86 of 87 isolates
also agreed with the ELISA and neutralization results. Although the SLT-II ELISA was specific for the SLT-II
variant produced by porcine edema strains, most of the isolates examined produced levels of toxin (<50 50%
cytotoxic doses [CD50] per ml) below the detection limit of the test. The ELISAs were not sufficiently sensitive
to consistently detect low levels of toxin (<50 CD50 per ml) found in fecal extracts. On the basis of these
findings, both ELISAs appeared to detect significant levels of SLT-I (>100 CD50 per ml) and SLT-II (>50 CDo
per ml) in E. coli culture extracts and should be useful diagnostic tools in many microbiology laboratories.
Shiga-like toxin-producing Escherichia coli (SLTEC) has
been associated with hemorrhagic colitis (3, 26, 28-30),
hemolytic uremic syndrome (HUS) (4, 13), and thrombotic
thrombocytopenic purpura (5). Primarily, one E. coli sero-
type, 0157:H7, has caused outbreaks of disease in a variety
of settings, including nursing homes (27, 31), day care
centers (34), and the community (3, 22, 31). In addition to E.
coli 0157:H7, other SLTEC serotypes have been associated
with sporadic cases of hemorrhagic colitis and HUS (1, 20).
E. coli, which produces a variant of Shiga-like toxin Il
(SLT-II), has been associated with edema disease in swine
(16, 21).
SLTEC associated with human illnesses does not produce
heat-labile or heat-stable E. coli enterotoxins and is not
invasive, as determined by the Sereny test (3, 39). SLTEC
associated with human illnesses, however, produces moder-
ate to high levels of at least two antigenically distinct toxins
referred to as SLT-I, or verotoxin 1, and SLT-II, or vero-
toxin 2 (14, 32, 36). SLT-I is neutralized by antibodies
against purified Shiga toxin from Shigella dysenteriae type 1
(25), while SLT-II is not neutralized. Conversely, antibodies
against SLT-II do not neutralize SLT-I or Shiga toxin (32,
36). The antigenic, biologic, and genetic relationships be-
tween Shiga toxin and the Shiga-like toxins have been
reviewed recently by O'Brien and Holmes (24).
Since its recognition in 1982 (30), E. coli 0157:H7 has
been recognized as a pathogen of public health significance;
however, the relative importance of E. coli 0157:H7 and
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other SLTECs as causes of diarrhea, hemorrhagic colitis,
and HUS has been difficult to assess because most clinical
and public health microbiology laboratories do not routinely
screen for these organisms. Simple, rapid diagnostic tech-
niques are needed not only to establish the epidemiological
characteristics of SLTEC strains but also to control person-
to-person transmission in potential outbreak situations.
Also, early diagnosis should aid clinicians in monitoring
patients for the development of HUS and in timely applica-
tion of appropriate HUS therapies.
The currently available laboratory techniques for detect-
ing SLTEC either focus on the isolation of E.coli 0157:H7
only or require facilities and personnel able to accommodate
cell culture assay or radiolabeled DNA probes. With the
availability of SLT-I- and SLT-II-specific monoclonal and
polyclonal antibodies, we were able to develop toxin-specific
enzyme-linked immunosorbent assays (ELISAs). The SLT-I
and SLT-II ELISAs are not based on the identification of an
unusual biochemical characteristic of E. coli 0157:H7 but
directly detect Shiga and Shiga-like toxins. These tests are
sensitive, specific, and easy to perform and therefore should
be useful in a variety of laboratory settings.
MATERIALS AND METHODS
Strains. E. coli strains of human origin from the United
States included in this study were isolated from the stools of
ill persons during sporadic episodes or outbreaks of illness.
Two E. coli strains (0111:NM and Ound:H7) were isolated
from the stools of persons with bloody diarrhea in rural
Bangladesh, bovine SLTECs were isolated from cattle
stools, and porcine edema disease strains were supplied by
D. Francis of South Dakota University, Brookings. Strain
EDL931 of E. coli 0157:H7, used as an SLT-I- and SLT-
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II-producing control strain, was isolated during the 1982
outbreak (30). SLT-I-producing strain H30 of E. coli 026:
H11, nontoxigenic E. coli (rough) HS, the prototype porcine
edema strain (S1191), and strain 60R of Shigella dysenteriae
type 1 were kindly supplied by A. D. O'Brien of the
Uniformed Services University of the Health Sciences,
Bethesda, Md. E. coli 0157:H7, Centers for Disease Control
strain B1409-C1, was used as an SLT-II-producing control
strain. The identity of all strains was confirmed by biochem-
ical characterization, and serotyping was done according to
the procedure of Ewing (8).
Antisera. The preparation of rabbit polyclonal antisera
(SLT-I: R174 and SLT-II: TB-6/24) against SLT-I and SLT-
II was previously described (7). SLT-I-specific monoclonal
antibody was prepared in BALB/c mice (ascites fluid) with
hybridoma 13C4 kindly supplied by A. D. O'Brien (35).
SLT-II-specific monoclonal antibody was prepared as above
with a hybridoma (BC5 BB12) developed in our laboratory
(7). The ascites fluids (containing monoclonal antibodies)
were treated with thrombin (1 U/ml) (Parke-Davis, Morris
Plains, N.J.) to remove fibrin, divided into portions, and
stored at -70°C until needed.
Gene probe hybridization. Isolates, including the control
strains H30, B1409-C1, and EDL931, were inoculated onto
MacConkey agar plates. Duplicates of each culture plate
were prepared to be used with the SLT-I and SLT-II gene
probes. Plates were incubated overnight at 37°C. Bacterial
growth was transferred to cellulose filters (541 paper; What-
man Ltd., Maidstone, England), and the bacterial DNA was
subsequently released and denatured with steam at alkaline
pH levels according to the procedure of Maas (17). SLT-I
and SLT-II gene probes (kindly supplied by J. W. Newland
and R. H. Neill, Walter Reed Institute of Research, Wash-
ington, D.C.) consisted of internal restriction fragments
cloned from toxin structural genes [J. W. Newland and R. H.
Neill, Abstr. Int. Symp. Workshop on Verocytotoxin (Shiga-
like toxin)-producing Escherichia coli, 1987, abstr. no.
GEN-4]. The probes were labeled with [32P]dCTP (New
England Nuclear Corp., Boston, Mass.) by nick translation
(Nick Translation reagent kit; Bethesda Research Laborato-
ries, Inc., Gaithersburg, Md.), and labeled probe DNA was
separated from unincorporated label with a disposable an-
ion-exchange column (NACS Prepac column; Bethesda Re-
search Laboratories, Inc.). Filters were prehybridized for 1
h at 68°C in hybridization solution (2x standardized saline
citrate, 5x Denhardt solution, 0.1% [wt/vol] sodium dodecyl
sulfate, 100 ,ug of denatured salmon sperm DNA [type III
sodium salt; Sigma Chemical Co., St. Louis, Mo.] per ml)
(19). Before hybridization, labeled probes were denatured by
boiling for 4 min and immediately diluted to 105 cpm/ml of
hybridization solution. Filters and approximately 2 x 106
cpm of labeled probe diluted in hybridization solution were
sealed in plastic bags and allowed to hybridize at 68°C
overnight. Subsequently, filters were washed once for 10
min at room temperature in 2x standardized saline citrate
and 0.1% sodium dodecyl sulfate and twice for 1 h at 68°C in
0.2x standardized saline citrate and 0.1% sodium dodecyl
sulfate. Filters were dried and incubated with Kodak X-
Omat AR X-ray film overnight at -70°C. Colonies which
hybridized with specific gene probes produced darkened
areas on the X-ray film.
Culture extract preparation. A fresh culture of each strain
was streaked onto a heart infusion agar slant (Carr-Scarbor-
ough, Atlanta, Ga.). After overnight incubation at 37°C, the
confluent bacterial growth was flooded with 1 ml of poly-
myxin B sulfate (0.1 mg/ml in 0.01 M phosphate-buffered
saline [PBS]; 6, 12). The bacterial cells were immediately
suspended in the antibiotic solution, and the suspension was
transferred to a sterile 1.5-ml conical centrifuge tube. Tubes
were incubated at 37°C for a minimum of 30 min and
centrifuged in a desktop microcentrifuge for 10 min. The
resulting supernatant fluid was transferred to a sterile tube
and stored for up to 3 days at 4°C.
Stool extract. Approximately 1 g of stool, frozen without
transport medium, was suspended in PBS to give a 50%
(wt/vol) stool suspension. The stool suspension was centri-
fuged in a desktop microcentrifuge for 10 min, and the
supernatant fluid was transferred to a sterile tube. The
supernatant was centrifuged for an additional 10 min, and the
resulting supernatant was transferred to a sterile tube and
stored at 4°C until tested in the ELISAs and HeLa cell assay
for evidence of free fecal toxin (13).
Neutralization assay. Mouse ascitic fluid containing SLT-
I-specific antibody (13C4) was diluted in cell culture medium
to a concentration which neutralized 103 50% cytotoxic
doses (CD50) of crude Shiga toxin per ml. SLT-II-specific
rabbit polyclonal antiserum (TB-6/24) was used at a concen-
tration which neutralized 102 CD50 of crude SLT-II per ml.
Additionally, a combination antiserum was prepared by
mixing antibodies 13C4 and TB-6/24 to the same final neu-
tralizing titers as that of the individual antisera. Bacterial
culture extracts were diluted 1/10 in each of the following:
HeLa cell culture medium, 13C4 antibody, TB-6/24 anti-
body, and the combination antiserum. After 1 to 4 h at 37°C,
0.1 ml of the dilutions was transferred to HeLa cell micro-
dilution cultures and tested for cytotoxicity as described by
Gentry and Dalrymple (9).
SLT-I and SLT-II ELISA procedures. Bacterial culture
extracts were tested in both the SLT-I ELISA and the
SLT-II ELISA simultaneously by using half of a 96-well
U-bottom polystyrene microdilution plate (Dynatech Labo-
ratories, Inc., Alexandria, Va.) for each assay. Optimum
dilutions of ELISA reagents used were determined by block
titrations. All washing steps were done at room temperature
with wash-diluent buffer (PBS with 0.05% Tween 20 and 1%
fetal bovine serum). Peripheral wells were not used for
testing but were flooded with wash-diluent buffer during all
incubations.
Monoclonal antibodies 13C4 and BC5 BB12 were used as
antigen capture antibodies. Mouse ascitic fluids were diluted
1:800 in carbonate buffer, pH 9.6 (0.159% [wt/vol] Na2CO3,
0.293% [wt/vol] NaH3CO3, 0.002% [wt/vol] NaN2), and 100
,ul was added to appropriate microdilution plate wells. After
overnight incubation at 4°C in a moist chamber, the plates
were washed three times. (Sensitized plates could be stored
at 4°C for up to 3 months with the final wash left in place.)
Any remaining binding sites were blocked immediately be-
fore use with 0.5% evaporated milk (fat free) in PBS (100 ,ul
per well) for 30 min at room temperature.
To each reaction well, 50 ,ul of 0.5% evaporated milk
(fat free) in PBS and 50 ,ul of culture extract or stool extract
were added. Samples were assayed simultaneously in both
ELISAs and were tested at least in duplicate in each assay.
Extracts from positive and negative control strains (HS,
H30, B1409-C1, and EDL931) were included in each assay.
After 1 h of incubation at 37°C in a moist chamber, samples
were removed from wells and the plate was washed three
times. SLT-I-specific polyclonal antibody, R174, used in the
SLT-I ELISA, and SLT-II-specific polyclonal antibody,
TB-6/24, used in the SLT-II ELISA, were diluted 1:400 in
wash-diluent buffer and added (100 ,ul per well) to the
appropriate wells. After 1 h of incubation at 37°C in a moist
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FIG. 1. Dose response of purified SLT-I antigen in SLT-1
ELISA. No heterologous response was seen with purified SLT-II
antigen.
chamber, antibodies were removed and the plates were
washed three times. Alkaline phosphatase-labeled goat anti-
rabbit antiserum (Kirkegaard-Perry Laboratories) was di-
luted 1:400 in wash-diluent buffer, and 100 was added to
each well. After incubation at 37°C for 1 h in a moist
chamber, the plates were washed three times, and 100 ,ul of
enzyme substrate (p-nitrophenyl phosphate [Sigma]), 1 mg/
ml in diethanolamine buffer, pH 9.6 (9.7% [vol/vol] dieth-
anolamine, 0.02% [wt/vol] NaN3, 0.01% [wt/vol] MgCl2),
was added to each well. The plates were incubated at room
temperature for 30 min, after which the color development
was stopped by adding 50 pl of 3 N NaOH to each well. The
optical density (OD) at 401 nm for each well was determined
(Micro ELISA Reader; Dynatech) by using a peripheral well
as a blank.
RESULTS
Specificity and sensitivity of ELISA. A total of 50 toxin-
negative and 50 toxin-positive (31 SLT-I-positive and 19
SLT-II-positive by cytotoxin neutralization assay) isolates
were assayed in both ELISAs. The range of background OD
for negative cultures was 0.0 to 0.08, with a mean of 0.04 OD
for SLT-I ELISA and 0.025 for SLT-II ELISA. Background
OD similar to that of negative cultures was obtained with
SLT-I- and SLT-II-positive extracts in heterologous
ELISAs. The lowest OD obtained with any of the positive
cultures in homologous ELISA was 0.15, with a range of
0.15 to >1.8 OD. Based on the range of values obtained with
these controls, a 0.1-OD cutoff was used to determine the
presence or absence of SLT. The 0.1-OD cutoff corre-
sponded to approximately 10 to 20 CD50 of SLT-I and 2 to 10
CD50 of SLT-II. With this cutoff, both ELISAs were uni-
formly negative with negative control strains and positive in
homologous ELISA with the positive control strains used
throughout this study. The sensitivities of the SLT-I and
SLT-II ELISAs were also determined by assay of affinity-
purified SLT-I and SLT-II in their homologous ELISA. The
mean OD value obtained for each toxin dilution was plotted
against the previously determined protein content of that
dilution. These findings indicate that the SLT-I ELISA
detects as little as 200 pg of purified SLT-I (Fig. 1) and the
SLT-II ELISA detects as little as 75 pg of purified SLT-II
(Fig. 2).
SLT produced by SLTEC. Over 200 SLT-producing E. coli
strains isolated from ill or asymptomatic humans (Table 1)
and animals (Table 2) were tested with SLT-I and SLT-II
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FIG. 2. Dose response of purified SLT-II antigen in SLT-II
ELISA. No heterologous response was seen with purified SLT-I
antigen.
ELISAs, cytotoxin neutralization in HeLa cells, and DNA
probes. Except as noted below for porcine strains, the
presence and type of toxin detected with ELISA in culture
extracts were confirmed by cytotoxicity and neutralization
tests (100% specificity and sensitivity). Gene probe results
obtained to date on a subset of 87 strains generally agreed
with phenotypic data; the SLT-II probe was positive for one
strain which was negative by both ELISA and neutralization
(data not shown).
Initial ELISA and neutralization results did not agree as to
the type of toxin present in extracts from three isolates in
this study. The original tests indicated SLT-I only by ELISA
and SLT-I and SLT-II by neutralization. Subsequent retest-
ing of those strains resulted in detection of only SLT-I by
both tests. Although the ELISA and neutralization tests
agreed, when a large number of strains were routinely
retested, four strains gave discrepant results. Three of these
isolates originally tested for SLT-I only; both SLT-I and
SLT-II were detected on subsequent retesting. One isolate
originally tested for SLT-I and SLT-II; only SLT-II was
detected in later analyses. The later results were corrobo-
rated by gene probe analysis.
Extracts from most of the porcine strains (Table 2) were
not cytotoxic to HeLa cells and had very low Vero cell toxin
titers. Extracts from these strains were consequently tested
for cytotoxicity and neutralized in Vero cells. Although the
ELISA was specific and as sensitive for the toxin produced
by these strains (SLT-II variant) as for SLT-II, most of the
porcine strains produced too little toxin (<50 CD50 per ml) to
be detected by ELISA. Additionally, extracts of stool from
HUS patients were tested directly in the ELISA and cyto-
toxin neutralization assay (Table 3). The SLT-II ELISA with
these extracts agreed with the neutralization and cytotoxic-
ity assays (100% sensitivity and specificity). The concentra-
tion of SLT-I in these extracts, however, was below the
detection limit (<100 CD50 per ml) of the SLT-I ELISA.
DISCUSSION
The classical method of detecting SLT activity is the cell
culture assay. SLT-I and SLT-II are both cytotoxic to HeLa
and Vero cell cultures (16, 25). Many SLTEC isolates are
often present in low numbers in stools (33, 39), and assaying
individual colonies as a screening technique in cell culture is
time-consuming and cumbersome. Karmali et al. (12) de-
scribed a colony sweep technique which is useful for screen-
ing large numbers of colonies from a single isolation plate.
The toxins, when present in sufficient amounts, can also be
detected by cell culture assay of stool extracts (13).
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TABLE 1. Use of SLT-I and SLT-II ELISAs for the detection
and identification of SLTs produced by human E. coli strains
No. of strains positive by
Disease and Total no. ELISA': No. of
serotype of strains strainstested SLT-I SLT-II SLT-1 and negative
SLT-II
HUS
0157:H7 34 2 4 28 0
0157:NM 2 0 0 2 0
0165:H25 1 0 1 0 0
0121:H19 1 0 1 0 0
0125ac:NM 1 1 0 0 0
Hemorrhagic colitis
0157:H7 44 2 4 38 0
0157:NM 7 2 1 4 0
Ound:NM 2 1 1 0 0
050:H7 3 0 1 0 2
050:NM 1 1 0 0 0
0111:NM 1 0 0 1 0
0111:H8 1 0 0 1 0
04:NM 1 0 0 1 0
026:H11 1 1 0 0 0
0145:NM 1 1 0 0 0
045:H2 1 1 0 0 0
Diarrhea
0157:H7 36 4 5 27 0
0157:NM 2 1 0 1 0
0157:Hund 1 0 0 1 0
0111:NM 2 2 0 0 0
Ound:H7 1 1 0 0 0
Ound:NM 1 0 0 1 0
Rough: 1 0 0 0 1
Otherb
0157:H7 5 1 0 3 1
0157:Hund 2 0 1 1 0
Asymptomaticc
0157:H7 2 0 0 2 0
Olab:H20 1 0 0 0 1
NTd 10 0 0 0 10
a Toxins identified by ELISAs were confirmed by cytotoxin neutralization
in HeLa cells.
b Other, Disease other than enteric.
C Asymptomatic, Isolated from non-ill persons who were in close contact
with HUS or hemorrhagic colitis patients.
d NT, Not 0157, not further identified.
We have found the cytotoxin neutralization test in HeLa
cells occasionally to be difficult to interpret due to variable
cell growth. In addition, HeLa cells could not be used to
detect or identify the variant SLT-II produced by porcine
edema strains. When the neutralization and ELISA tests did
not agree in this study, the fault was found to be in the
reading of the neutralization test or due to very low levels of
toxin. Although the ELISAs were less sensitive than the
neutralization test, they were specific, took less time, and
were easier to perform and interpret. The slightly lower
sensitivity did not affect the reliability of the ELISAs (100%
specificity and sensitivity) for detection and identification
of toxins produced by moderate- to high-toxin-producing
strains. The production of low levels of these toxins does
not correlate with SLT probe reactions and human illness.
On the basis of these data and continuing experience with
these tests in our laboratory (unpublished data), we believe
TABLE 2. Use of SLT-I and SLT-II ELISAs for the detection
and identification of SLTs produced by E. coli
isolated from animal sources
No. of strains positive by
Source and Total no. ELISA': No. ofSource d of strains strainsserotype tested SLT-1 SLT-II SLT-I and negative
SLT-Il
Bovine stool
0157:H7 4 0 4 0 0
0157:NM 1 0 1 0 0
045:H2 2 2 0 0 0
045:NM 2 2 0 0 0
OX3:NM 2 0 2 0 0
Rough:NM 5 1 4 0 0
OO:NM 1 1 0 0 0
0103:NM 1 1 0 0 0
026:H11 1 1 0 0 0
0171:H2 2 0 2 0 0
0111:NM 2 2 0 0 0
0145:NM 1 0 1 0 0
Ound:NM 1 1 0 0 0
NTh 24 0 O O 24
Venison stool, 2 0 2 0 0
0157:H7
Porcine stools
0138:- 3 0 2 0 1
NT 5 0 0 0 5
a Toxins identified by ELISA were confirmed by cytotoxin neutralization in
HeLa cells.
b NT, Serotype not determined.
'Toxin titrations and neutralization tests were performed in Vero cells for
the porcine strains. The neutralization test and ELISA agreed for only two of
the eight strains tested (see text).
these ELISAs will reliably detect toxin in culture extracts
from all significant SLTEC isolates.
Although results of the neutralization test and ELISAs
were in agreement, four strains were found to exhibit dif-
ferent toxins when tested at a later date than those found
originally. The reason for this discrepancy is not known but
was not observed with several other retested strains or with
any of the control strains used throughout this study. A
change from SLT-I and SLT-II production to only SLT-II
production could be caused by the loss of toxin-mediating
bacteriophage. Also, we have observed that the quantity of
toxin produced by some strains varies in extracts prepared at
different times, and this is a potential source of error in both
tests.
Toxin-specific gene probes have been described by Smith
et al. (33) and Newland and Neill [Newland and Neill, Abstr.
Int. Symp. Workshop on Verocytotoxin (Shiga-like toxin)-
producing Escherichia coli, 1987]. Smith et al. reported that
DNA hybridization was a sensitive technique for detecting
low numbers of SLTEC of any serotype from spread-plate
cultures or serially diluted stool specimens. Gene probes are
apparently a useful diagnostic technique, but the cost of
reagents with short shelf lives and concerns of handling and
disposal of radionucleotide-labeled DNA limit the wide-
spread applicability of this method. At this time, we are
unable to explain the positive probe reaction and negative
phenotypic assays for SLT-II in one strain.
Epidemiological data obtained from outbreak investiga-
tions indicate that SLT-II production is at least as important
as SLT-I production as a potential virulence factor (Centers
for Disease Control, personal communications). Therefore,
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TABLE 3. Free fecal SLT identified by cytotoxin neutralization
and SLT-I and SLT-II ELISAs
Presence (+) or absence (-) of indicated
toxin as detected by:
Patient Stool
sample Neutralization ELISA
SLT-I SLT-II SLT-I SLT-II
1 B9597
B9598 - - - -
B9599 - - - -
B9604a + + _ +
2 B9600a + + - +
B9601 - - - -
B9603 - - - -
B9605 - - - -
3 B9602 - - - -
4 A - - - -
5 B - - - -
6 B9193a + - - _
7 B9194a - + - +
8 B9206a + + - +
9 B9207a + + - +
10 C - - - -
a 0157:H7 colonies isolated from these stools.
a useful immunodiagnostic test for SLTEC must be able to
detect both toxins. Although two immunoassays, one an
immunoblot procedure, have been described for SLT-I, no
immunoassay specific for SLT-II had been reported at the
time of this study (15, 35). By using a monoclonal antibody
previously described for SLT-I (35) and recently developed
SLT-II-specific monoclonal and SLT-I- and SLT-II-specific
polyclonal antisera (7), we were able to develop a set of
sensitive and specific ELISAs which detected E. coli strains
that produced either or both toxins. With the availability of
SLT-II-specific monoclonal antibodies, the immunoblot as-
say may also be modified to detect both toxins.
We selected the sandwich ELISA format that was used
successfully for E. coli enterotoxins for both SLT-I and
SLT-II (37, 38). This format is generally more sensitive than
a direct immunioassay, possibly due to the second antibody
binding to multiple sites on the captured antigen (40, 41).
Also, the direct ELISA procedure requires antibody enzyme
labeling by the tester. Although an additional incubation step
is required in the sandwich ELISA, this format may be more
reproducible and easier to perform because the necessary
enzyme-labeled conjugate is commercially available.
The SLT-I ELISA was sensitive to 200 pg of purified
SLT-I, and the SLT-II ELISA was sensitive to 75 pg of
purified SLT-II. Based on the reported specific activities of
affinity-purified toxins in HeLa cell culture, the SLT-I
ELISA should detect approximately 200 CD50 of SLT-I per
ml and the SLT-II ELISA should detect approximately 70
CD50 of SLT-II per ml. We speculate that the difference in
the sensitivities of the ELISAs may be due to characteristics
of the antibodies used in each assay.
Results from both Canadian and American surveys (10,
11, 18) indicate that E. coli 0157:H7 is a frequently isolated
enteric pathogen. Neill et al. (23) reported that this organism
was the most frequently isolated enteric pathogen in cases of
HUS with a prodrome of bloody diarrhea. Additionally, E.
coli 0157:H7 in outbreak situations was also frequently
isolated from individuals with nonbloody diarrhea or who
were asymptomatic (31). The relative importance of SLTEC
serotypes other than 0157:H7 as a cause of diarrhea, bloody
diarrhea, hemorrhagic colitis, and HUS is difficult to assess
because screening protocols used in surveys have focused
on isolation of E. coli 0157:H7. The availability of the SLT-I
and SLT-II ELISAs should facilitate testing for SLTEC and
lead to a better understanding of the epidemiology of this
group of E. coli isolates associated with human illness.
Early diagnosis of SLTEC infections is important in
controlling person-to-person transmission in outbreak situa-
tions and in monitoring infected individuals for development
of more severe illness such as HUS or thrombotic thrombo-
cytopenic purpura. Antibiotic therapy has not been docu-
mented to influence the duration of symptoms or adverse
outcome of SLTEC infections (2, 30). With the availability of
these simple, rapid, diagnostic assays, more controlled stud-
ies of appropriate antibiotic and supportive therapies may be
investigated. The toxin-specific immune reagents used in this
study (7, 35) may also be useful to researchers in purifying
large quantities of toxins and clarifying the role of the SLT in
the pathogenesis of hemorrhagic colitis, HUS, and throm-
botic thrombocytopenic purpura.
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